All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional.
Introducing
Now you can personalise
your GvHD Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe GvHD Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the GvHD Hub cannot guarantee the accuracy of translated content. The GvHD Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
Results from a phase III trial of belumosudil as a second or subsequent line of therapy in Japanese patients aged ≥12 years with steroid-dependent/resistant chronic graft-versus-host disease (cGvHD) were presented during the European Hematology Association (EHA) 2024 Hybrid Congress by Onishi.1 This analysis evaluated the safety and efficacy of belumosudil at 48 weeks after the last patient enrolment.1 |
Key learnings: |
The best overall response rates at 24 weeks (primary efficacy endpoint) and 48 weeks after last patient enrolment were both 85.7%. |
The median duration of response was 68.1 weeks, and the median failure-free survival and overall survival were not reached. |
No new safety concerns were observed, and there were no drug-related discontinuations or deaths. |
The high response rates and tolerable safety profile demonstrated in this trial support the use of belumosudil as a second or subsequent line of therapy in the treatment of Japanese patients aged ≥12 years with steroid-dependent/resistant cGvHD. |
Your opinion matters
Subscribe to get the best content related to GvHD delivered to your inbox